We believe serious diseases deserveserious attention
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. A leader in muscle biology research with approximately 25 publications, 50 clinical trials, and more than 200 issued patents, Cytokinetics is developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Cytokinetics was founded by pioneers in the field of muscle biology. Over the years, our company has developed an unparalleled expertise, keeping it at the forefront of drug discovery and development for diseases impacting muscle performance. Muscle plays a critical role in everyday physical functionality, including proper circulation, movement, and even the ability to breathe. As a result, conditions or syndromes that lead to dysfunction of muscle have serious consequences on survival and well-being.
Cytokinetics takes a purpose-driven approach by leveraging our unique muscle biology expertise to engineer compounds with specific characteristics aimed at treating diseases that impact muscle function. By increasing muscle strength and performance, the treatments we are developing have the potential to preserve and extend independence and self-reliance in people suffering from debilitating diseases. Cytokinetics is dedicated to helping underserved patient populations which lack effective therapies.
Cytokinetics scientists have discovered a robust pipeline of small molecule muscle activators including tirasemtiv, our Phase 3 drug candidate for people living with ALS; omecamtiv mecarbil, our Phase 2 drug candidate for people living with heart failure; and CK-2127107 (CK-107), our Phase 2 drug candidate for people living with SMA, COPD and ALS. Our muscle biology drug discovery and development platform has great potential for many other diseases and medical conditions characterized by muscle weakness, fatigue, or diminished muscle function.
In 2006, Amgen and Cytokinetics entered into a strategic alliance to discover, develop, and commercialize novel small molecule therapeutics designed to activate cardiac muscle for the potential treatment of heart failure. Initially, following Amgen’s option exercise in 2009, the collaboration was worldwide, excluding Japan. The companies expanded the collaboration in 2013 to provide Amgen with worldwide rights to develop and commercialize omecamtiv mecarbil and related compounds for the treatment of heart failure subject to development and commercial participation rights of Cytokinetics. Cytokinetics can elect to co-fund Phase 3 development costs, in which case Cytokinetics has the right to co-promote approved co-funded products in North America in institutional care settings.
In 2013, Astellas and Cytokinetics formed a partnership focused on the research, development, and commercialization of skeletal muscle activators. The primary objective of the collaboration is to advance novel therapies for diseases and medical conditions associated with muscle impairment and weakness. Under the collaboration, Cytokinetics exclusively licensed to Astellas rights to co-develop and potentially co-commercialize CK-107 in non-neuromuscular indications. In 2014, Astellas and Cytokinetics agreed to expand the collaboration to include certain neuromuscular indications, including SMA. Currently, CK-107 is being studied in Phase 2 studies in patients with SMA and chronic obstructive pulmonary disease (COPD).
In July 2016, Cytokinetics and Astellas announced expansion of the collaboration to include ALS. Through this expansion, Cytokinetics granted Astellas an option right for the development and commercialization of tirasemtiv; if Astellas exercises the option, Astellas will receive exclusive worldwide commercialization rights outside of Cytokinetics’ commercialization territory of North America, Europe and other select countries. The companies also agreed to amend their collaboration agreement to enable the development of CK-107 for the potential treatment of ALS and to extend their joint research focused on the discovery of additional next-generation skeletal muscle activators through 2017.